top of page
gradientForSurfBreak.png

Item List

PR Newswire
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing

Invitae ( NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae's Ciitizen platform were utilized as natural history data to support the submission of Praxis' Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy (DEE). Praxis announced earlier this month that the U.S. Food and Drug Administration (FDA) cleared the IND application for the initial dose cohort for the PRAX-222 EMBRAVE clinical study.

Recent Posts

Portfolio Company

Carlsmed.png

Marigold Health Secures $11m in Series A Funding to Expand Peer Support
...

Busineswire

Portfolio Company

Carlsmed.png

Materna Medical Launches Groundbreaking Virtual Clinical Trial Evaluating Treatm ...

Yahoo Finance

Portfolio Company

Carlsmed.png


Clarified Precision Medicine, xCures Partner to Improve Clinical Decision Suppo ...

Precision Medicine Online

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page